Neuren Pharmaceuticals shares an update on the the company's Angelman Syndrome Clinical Study. July 8, 2023
Ann: Neuren commences Phase 2 trial of NNZ-2591 in Angelman, page-18
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.80 |
Change
-0.120(0.86%) |
Mkt cap ! $1.744B | |||
| Open | High | Low | Value | Volume |
| $13.94 | $13.96 | $13.50 | $2.991M | 218.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 165 | $13.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.80 | 613 | 18 |
View Market Depth
| Last trade - 13.27pm 06/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |